Assembly Biosciences (ASMB) Cash from Financing Activities (2010 - 2026)

Assembly Biosciences' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $149000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 92.25% year-over-year to $149000.0 in Q1 2026; TTM through Mar 2026 was $172.9 million, a 451.13% increase from a year earlier, with the FY2025 full-year figure at $174.7 million, up 493.12% from the prior year.
• Cash from Financing Activities declined to $149000.0 in Q1 2026 per ASMB's latest filing, from $456000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $171.9 million in Q3 2025 and bottomed at $134000.0 in Q2 2023.
• The 5-year median for Cash from Financing Activities is $1.2 million (2025), against an average of $18.2 million.
• Across the five-year window, Cash from Financing Activities surged 9194.03% in 2024 and tumbled 97.32% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $437000.0 in 2022, then jumped by 2003.43% to $9.2 million in 2023, then jumped by 84.89% to $17.0 million in 2024, then tumbled by 97.32% to $456000.0 in 2025, then plunged by 67.32% to $149000.0 in 2026.
• Per Business Quant, the three latest ASMB Cash from Financing Activities figures stand at $149000.0 (Q1 2026), $456000.0 (Q4 2025), and $171.9 million (Q3 2025).